



**ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 20271

**Title:** Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma

**Reviewer’s code:** 02992426

**Reviewer’s country:** Taiwan

**Science editor:** Jin-Xin Kong

**Date sent for review:** 2015-06-05 10:17

**Date reviewed:** 2015-08-05 10:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

**COMMENTS TO AUTHORS**

This is a study describing the treatment outcome of CyberKnife stereotactic body radiotherapy (SBRT) to primary or metastatic lesions in patients with advanced or terminal hepatocellular carcinoma according to Barcelona Clinic Liver Cancer classification. However, major revision is recommended in order to interpret the result of current study clearly. Major comments: 1. Please clarify how to select targeted tumors eligible for SBRT, especially for those patients with multiple metastases. 2. Please clarify if the included patients received other cancer specific therapies other than SBRT. 3. Please analyze the relationship between treatment response and patient/tumor characteristics, as well as the change of tumor markers. 4. Please clarify the definition of pain relief in patients with symptomatic bone metastasis. Minor comment: 1. In addition to classical radiation induced liver disease (RILD), please document non-classical RILD as well.